Guardant Health price target raised to $60 from $57 at Scotiabank

Scotiabank analyst Sung Ji Nam raised the firm’s price target on Guardant Health (GH) to $60 from $57 and keeps an Outperform rating on the shares. The company’s Q2 results beat expectations across the board and FY25 revenue guidance was raised once again, the analyst tells investors. The company’s Guardant360 portfolio shows continued strength and Shield has exceeded the firm’s expectations in its first year commercially, Scotiabank adds.